Avalo Therapeutics AVTX Change in fair value of derivative liability
Change in fair value of derivative liability at other companies
Other financials
Where this comes from
Reported directly by Avalo Therapeutics in its filing.
Tagged under the XBRL concept avtx:FairValueAdjustmentOfDerivativeLiability.
The official record: Avalo Therapeutics’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avalo Therapeutics's change in fair value of derivative liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avalo Therapeutics's change in fair value of derivative liability?
- Avalo Therapeutics (AVTX) reported change in fair value of derivative liability of $480K in Q1 2026.
- How has Avalo Therapeutics's change in fair value of derivative liability changed year-over-year?
- Avalo Therapeutics's change in fair value of derivative liability increased by 26.3% year-over-year, from $380K to $480K.
- What is the long-term trend for Avalo Therapeutics's change in fair value of derivative liability?
- Over 2 years (2023 to 2025), Avalo Therapeutics's change in fair value of derivative liability has grown at a 248.8% compound annual growth rate (CAGR), from -$720K to -$8.76M.
- What does change in fair value of derivative liability mean?
- This reflects the non-cash gain or loss resulting from changes in the market value of derivative instruments classified as liabilities. Because these adjustments are driven by market volatility rather than core operational performance, they are excluded from cash flow from operations to provide a clearer view of underlying business health. Monitoring this helps investors assess the impact of financial engineering and market-linked obligations on the company's bottom line.